References
- Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 399: 71–85
- Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. New Engl J Med 1995; 332: 901–6
- Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991; 9: 2134–40
- Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273: 542–7
- Wood W C, Budman D R, Korzun A H, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New Engl J Med 1994; 330: 1253–9
- Habibollahi F, Fentiman I S, Chaudary M A, et al. Influence of radiotherapy on the dose of adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 1989; 13: 237–41
- Ribas A, Albanell J, Bellmunt J, et al. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol 1996; 14: 1573–80
- Hryniuk W M, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162–70
- The American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471–508
- Griem K L, Henderson I C, Gelman R, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 1987; 5: 1546–55
- Overgaard M, Christensen J J, Johansen H, et al. Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. Int J Radiat Oncol Biol Phys 1990; 19: 1121–4
- Peters W P, Ross M, Vredenburgh J J, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–43
- Schmidberger H, Hess C F, Hoffmann W, et al. Granulocyte colony-stimulating factor treatment of leucopenia during fractionated radiotherapy. Eur J Cancer 1993; 29A: 1927–31
- Vokes E E, Haraf D J, Mick R, McEvilly J M, Weichselbaum RR. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994; 12: 2351–9